

Supplemental Figure 1. Expression of NFAT5 in the mouse models used in this study, as well as pro- and anti-inflammatory genes in wild-type and NFAT5-deficient macrophages. (**A**) Suppression of NFAT5 mRNA expression in peritoneal CD11b macrophages of LysM-Cre *Nfat5* $^{fl/fl}$ mice. (**B**) Suppressed NFAT5 mRNA expression in different hematopoietic lineages (peritoneal macrophages, spleen T and B cells), but not in non-hematopoietic tissues (muscle and skin) in Vav-Cre *Nfat5* $^{fl/fl}$ mice. (**C**) Specific loss of NFAT5 mRNA in BMDM, T and B cells from Mx-Cre *Nfat5* $^{fl/fl}$ (KO) mice upon treatment with polyIC. (**D**) Western blots show representative experiments comparing NFAT5 protein expression in wild-type (W) and Vav-Cre *Nfat5* $^{fl/fl}$ BMDM or Mx-Cre *Nfat5* $^{fl/fl}$ BMDM (K). (**E**) Expression of the indicated genes in wild-type (Vav-Cre *Nfat5* $^{+/+}$) and NFAT5-deficient (Vav-Cre *Nfat5* $^{fl/fl}$) macrophages, either without pretreatment or pretreated 24h with IFNγ or IL-4, and then stimulated with LPS as indicated. Values for each gene are represented relative to the respective stimulatory conditions that induced maximal expression in wild-type macrophages (100%), and show the mean ± SEM of 3 independently performed experiments. Statistical significance was determined with an unpaired *t* test (**A**, **C**) or a two-way ANOVA test (**E**) (*$p < 0.05$; **$p < 0.01$).



Supplemental Figure 2. Responsiveness of wild-type peritoneal macrophages to ID8-Luc ovarian cancer cells. (**A**) Flow cytometry gating strategy for the analysis of peritoneal macrophage subsets, as well as peritoneal macrophage subset composition in naïve peritoneum and different days after ID8-Luc inoculation. (**B**) Proportions of tumor associated macrophage (TAM) subsets, and naïve and effector CD4 and CD8 T cells in naïve peritoneum and different days after ID8-Luc inoculation. Note that values for day 0 correspond to resident peritoneal macrophage subsets in the naïve peritoneum, analyzed with the same markers and gating strategy used to define TAM subsets in ID8-Luc-bearing mice. (**C**) mRNA expression of the indicated genes in CD11b$^+$ macrophages in naïve peritoneum and different days after ID8-Luc inoculation. (**D**) ID8-Luc tumor burden was assessed by intravital luminescence. Results in B through D show the mean ± SEM of 3 to 4 analyzed mice.



Supplemental Figure 3. Analysis of wild-type and NFAT5-deficient tumor-associated macrophages in ID8-Luc and LLC tumor models. (**A**) Comparison of mRNA levels of the indicated genes in peritoneal CD11b$^+$ macrophages isolated at days 7 and 36 after ID8-Luc inoculation. (**B**) proportion of tumor-associated macrophage (TAM) subsets in peritoneal exudates of the same mice. Results in (**A**) and (**B**) correspond to experiments shown in Figure 6A. Statistical significance was determined with an unpaired Mann Whitney test (**A**) and an unpaired *t* test (**B**). (**C** and **D**) Gene expression (**C**) and proportion of TAM subsets (**D**) in CD11b$^+$ macrophages isolated from LLC tumors from the same mice (4 WT, 7 KO in (**C**), and 7 mice of each genotype in (**D**)) shown in Figure 6B.

Supplemental Table 1. Primers used for RT-qPCR.

Target gene		Primer sequence
Arg1	Forward	5'-CAC ACT GAC ATC AAC ACT CC-3'
Arg1	Reverse	5'-TCT CGC AAG CCA ATG TAC AC-3'
Ccl2	Forward	5'-CTC AGC CAG ATG CAG TTA ACG-3'
Ccl2	Reverse	5'-CAG ACC TCT CTC TTG AGC TTG G-3'
Ccr2	Forward	5'-ACC TCA GTT CAT CCA CGG CAT AC-3'
Ccr2	Reverse	5'-CAA GCT CCA ATT TGC TTC ACA-3'
Cd163	Forward	5'-CTG ATG GAG CAG ATC TGG AAC-3'
Cd163	Reverse	5'-CAG ATC CAC ATC CAA GCT GAC-3'
Chi3l3	Forward	5'-TCC ATG ATC CTA AGG ATG GC-3'
Chi3l3	Reverse	5'-ATG AGC TTC TCA GAA GCT GC-3'
Gas6	Forward	5'-GAG GAC ATC TTA CCA TGT GTGC-3'
Gas6	Reverse	5'-TGA AGC CTC TTG AAG CGT AG-3'
Ifng	Forward	5'-CTC AAG TGG CAT AGA TGT GG-3'
Ifng	Reverse	5'-CAG GTG TGA TTC AAT GAC GC-3'
Il12b	Forward	5'-AGA TGA AGG AGA CAG AGG AG-3'
Il12b	Reverse	5'-ACT TGC TGC ATG AGG AAT TG-3'
Il1b	Forward	5'-TGA AGA AGA GCC CAT CCT CTG-3'
Il1b	Reverse	5'-AGC TTT CAG CTC ATA TGG GTC-3'
Il2	Forward	5'-AGC TGT TGA TGG ACC TAC AG-3'
Il2	Reverse	5'-AAA TCC AGA ACA TGC CGC AG-3'
Il4	Forward	5'-CTC ACA GCA ACG AAG AAC ACC-3'
Il4	Reverse	5'-GCT TAT CGA TGA ATC CAG GC-3'
Il6	Forward	5'-GCC AGA GTC CTC CAG AGA GAT AC-3'
Il6	Reverse	5'-CCA CTC CTT CTG TGA CTC CAG C-3'
L32	Forward	5'-ACC AGT CAG ACC GAT ATG TG-3'
L32	Reverse	5'-ATT GTG GAC CAG GAA CTT GC-3'
Mrc1	Forward	5'-GGA CTC TGG ATT GGA CTC AAC AG-3'
Mrc1	Reverse	5'-GCT CTG ATG ATG GAC TTC CTG G-3'
Nfat5	Forward	5'-CAG CCA AAA GGG AAC TGG AG-3'
Nfat5	Reverse	5'-GAA AGC CTT GCT GTG TTC TG-3'
Nos2	Forward	5'-AGC TGG GCT GTA CAA ACC TT-3'
Nos2	Reverse	5'-CTC CCA TGT TGC ATT GGA AG-3'
Retnla	Forward	5'-CAG CTG ATG GTC CCA GTG AAT A-3'
Retnla	Reverse	5'-GGC CCA TCT GTT CAT AGT CTT GAC-3'
Tnfa	Forward	5'-TCG TAG CAA ACC ACC AAG TG-3'
Tnfa	Reverse	5'-GGA GTA GAC AAG GTA CAA CC-3'